← Back to Search

Cancer Vaccine

Treatment - Investigational Product for Cancer

Phase 2
Recruiting
Research Sponsored by Elios Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient must be ≥18 years of age
Patient must have a site of disease with planned incisional or excisional procedure expected to result in sufficient tissue for vaccine creation, or must be amenable to biopsy and be a candidate for tumor biopsy with anticipated sufficient tumor tissue resulting to vaccine creation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Study Summary

This trial aims to learn about a cancer vaccine for solid tumor malignancies & its effects on survival, safety & immune response.

Who is the study for?
This trial is for individuals with various types of solid tumor cancers, including those that have spread (metastasized). Participants must meet certain health standards but specific inclusion criteria are not listed. People who do not meet the study's requirements or have conditions that might interfere with the vaccine's effects will be excluded.Check my eligibility
What is being tested?
The TLPO vaccine, made from a patient's own tumor cells, is being tested to see if it can slow down cancer progression or recurrence and improve survival rates. The study also evaluates safety based on standard criteria and checks whether the vaccine triggers an immune response against cancer.See study design
What are the potential side effects?
While specific side effects are not detailed here, they will be monitored using standardized adverse event criteria. Side effects could range from mild injection site reactions to more significant immune-related responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I can undergo a procedure to provide enough tissue for a cancer vaccine.
Select...
I am fully active or can carry out light work.
Select...
I do not have any severe health issues that are not under control.
Select...
I do not have any current infections.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to Disease Progression
Secondary outcome measures
Number of participants with treatment-related adverse events per CTCAE v5.0
Overall survival (OS) after vaccination
Other outcome measures
Disease Control Rate
Duration of Response
Immune Response after vaccination
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment - Investigational ProductExperimental Treatment1 Intervention
Product Name: Tumor lysate, particle only (TLPO) vaccine Dosage Form: Intradermal Injection Unit Dose: 1x10^8 autologous tumor lysate-loaded, yeast cell wall particles Route of Administration: Intradermal; primary vaccine series at 0, 1, 2 months followed by boosters at 6, 9, and 12 months Physical Description: 250 uL clear liquid vials Manufacturer: Elios Therapeutics, LLC

Find a Location

Who is running the clinical trial?

LumaBridgeUNKNOWN
3 Previous Clinical Trials
92 Total Patients Enrolled
Elios Therapeutics, LLCLead Sponsor
2 Previous Clinical Trials
210 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current sample size of this clinical exploration?

"Indeed, the information published on clinicaltrials.gov declares that this examination is currently seeking participants. This trial was initially posted on November 29th 2023 and recently updated December 8th of the same year. The study seeks to recruit 100 individuals from a single location."

Answered by AI

What has been determined about the safety of Treatment - Investigational Product for patients?

"Our evaluation of Treatment - Investigational Product's safety registered a score 2 as Phase 2 trials have provided some evidence for its security, but not yet for its effectiveness."

Answered by AI

Are there any open enrollment opportunities for this clinical experiment?

"The clinicaltrials.gov portal attests that this research is currently seeking participants; the trial was first posted on November 29th 2023, and its information was most recently revised on December 8th 2023."

Answered by AI

Who else is applying?

What site did they apply to?
Southside Medical Center
What portion of applicants met pre-screening criteria?
Met criteria

What questions have other patients asked about this trial?

How long are visits ? Flexibility to schedule visits?
PatientReceived 1 prior treatment

Why did patients apply to this trial?

Recent research and studies
clinicaltrials.govStudy
Autologous TLPO Vaccine Basket
2023. "Autologous TLPO Vaccine Basket". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06175221.
All > Columbia
~67 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top